Navigation Links
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Date:4/26/2009

)."

Phase 3 Trial Design

The multicenter, randomized, double-blind, placebo-controlled Phase 3 study enrolled patients with unresectable stage III or stage IV melanoma at more than 200 clinical sites in the United States and Australia. The primary efficacy endpoint was overall survival, and secondary endpoints included progression-free survival and response rate.

Patients were randomized to receive 400 mg oral Nexavar twice daily or placebo, in addition to two chemotherapeutic agents - carboplatin and paclitaxel. Following 10 cycles of Nexavar or placebo plus chemotherapy, patients who achieved a response to the combination continued in a maintenance phase where Nexavar or placebo was administered as a single agent until disease progression.

About Melanoma

In 2007, more than 108,000 people worldwide (about 59,000 Americans) were diagnosed with melanoma and more than 40,000 of them (about 8,110 Americans) died from the disease. In the United States, the percentage of people who develop melanoma has more than doubled in the past 20 years. Melanoma accounts for about four percent of skin cancer cases but causes about 75 percent of skin cancer deaths.

Nexavar's Differentiated Mechanism

Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) - two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET.

Nexavar is currently approved in more than 70 countries for the treatment of patients with liver cancer and in more than 80 countries for the treatment of patients with advanced kidney cancer. Nexavar is also being evaluated by the companies, international study groups, g
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
4. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
7. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
8. Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
9. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
10. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty ... for the second quarter ended June 30, 2014. ... $6.5 million in the second quarter of 2014, an increase ... Total revenues of $13.3 million for the six months ended ... period in 2013 , Total revenues generated from the ...
(Date:7/24/2014)... ATLANTA , July 24, 2014  Alimera Sciences, ... company that specializes in the research, development and commercialization ... release its second quarter of fiscal year 2014 financial ... 2014. An investor conference call will follow on the ... The conference call will be hosted by Dan ...
(Date:7/24/2014)... BUFFALO, N.Y. , July 24, 2014  Kinex ... US FDA for the Company,s KX2-391 Ointment for the ... keratosis. This is the Company,s third IND to be ... months. KX2-391 is a synthetic, orally active ... and tubulin polymerization. KX2-391 promotes the induction of p53, ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... 26 Brainlab announced the availability of ExacTrac® Infrared Monitoring, ... during radiation therapy treatments, at the American Association of Physicists in ... , , ... tool used by many cancer care centers for patient setup; however, ...
... ,, ROCKVILLE, Md. , July 26 Sequella, Inc., ... announced today the publication of studies in the scientific journal Antimicrobial ... for the treatment of TB, and TMC207, Tibotec lead TB drug candidate: ... Reddy, V.M., L. ...
Cached Medicine Technology:Brainlab Offers Real-Time Monitoring for IGRT 2Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro 2Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro 3
(Date:7/24/2014)... York (PRWEB) July 24, 2014 ... ( http://www.injurybeacon.com/granuflo-dialysis/lawsuit/ ) in the U.S. District ... protective order for plaintiff medical information covered by ... According to the July 16th Order, U.S. District ... for Fresenius Medical Care the right to ...
(Date:7/24/2014)... Amy Norton HealthDay Reporter ... of the sex-crazed teenage boy may be dead wrong, according to ... romantic relationships. In interviews with 33 boys between the ages ... a relationship with a girl for the closeness and trust. Very ... goal" in starting a relationship with a girl. "In our ...
(Date:7/24/2014)... HealthDay Reporter THURSDAY, July ... don,t view their kids as unhealthy or recognize the health ... study. The children of the families surveyed for the ... Children,s Hospital in Providence, R.I. "A third categorized their ... Dr. Kyung Rhee, now an assistant professor of pediatrics at ...
(Date:7/24/2014)... found a way to delay or even prevent Alzheimer,s ... the anti-aging protein Klotho can prevent neuron death in ... These findings currently appear in the Journal of ... most frequent age-related dementia affecting 5.4 million Americans including ... more than 40 percent of people over the age ...
(Date:7/24/2014)... News Facts , Lexmark’s ... certification for compliance with Department of Defense (DoD) ... DoD Information Assurance Certification and Accreditation Process (DIACAP). ... the DoD as the Enterprise Clinical Imaging Archive, ... the U.S. Army Medical Materiel Agency. , DIACAP ...
Breaking Medicine News(10 mins):Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 2Health News:Teenage Boys Want Intimacy, Not Just Sex, Survey Finds 3Health News:Parents of Obese Kids Often View Them as Healthy 2Health News:Parents of Obese Kids Often View Them as Healthy 3Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 2Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 3Health News:Perceptive Software Achieves DIACAP Certification for Vendor Neutral Archive Solution to Support U.S. Department of Defense Integrated Clinical Systems Program 4
... Gives Washington Residents Access to Nursing Home, Assisted ... Nearly Every Zip Code Statewide RICHMOND, Va., April 30 ... in Washington is rising at a rate outpacing inflation, putting ... to an annual study by Genworth Financial. At the ...
... Utah Residents Access to Nursing Home, Assisted Living, Home Care ... Code StatewideRICHMOND, Va., April 30 The cost ... rate outpacing inflation, putting significant financial pressure on those in ... Financial. At the same time, the current economic downturn ...
... Assisted Living, Home Care and Adult Day Health Care Costs ... The cost of long term care in Rhode ... financial pressure on those in or near retirement, according to ... time, the current economic downturn has led to a decline ...
... middle-age and beyond, study suggests , , WEDNESDAY, April 29 (HealthDay ... much earlier in life than it currently does, say Canadian ... , The study of 400 women, ages 15 to ... young women may be associated with their risk for breast ...
... production system are biggest challenges, experts say , , THURSDAY, April ... swine flu pandemic, U.S. health officials are already collecting information ... vaccine. , And even though experts say there,s no guarantee ... -- would work, many agree it,s the logical next step. ...
... half of those surveyed believe agency is falling behind ... News) -- Although the American public feels a little ... Administration is doing now than a year ago, about ... safeguard the country,s food and drugs, a new Harris ...
Cached Medicine News:Health News:Growth in Washington Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Washington Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Washington Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:Growth in Utah Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Utah Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Utah Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:Growth in Rhode Island Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 2Health News:Growth in Rhode Island Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 3Health News:Growth in Rhode Island Long Term Care Costs Outpacing the Rate of Inflation, According to Annual Genworth Financial Study 4Health News:Young Women's Breast Tissue Offers Clues to Cancer Risk 2Health News:Swine Flu Vaccine Still Months Away 2Health News:Swine Flu Vaccine Still Months Away 3Health News:U.S. Public Lacks Confidence in FDA: Poll 2Health News:U.S. Public Lacks Confidence in FDA: Poll 3Health News:U.S. Public Lacks Confidence in FDA: Poll 4
... airways., ,When a difficult airway must ... Now you can be assured of rapid ... Esophageal/Tracheal double-Lumen Airway from Nellcor. Unlike traditional ... to establish a nonsurgical patient airway when ...
Guedel-style enclosed center channel. Semirigid, nontoxic polyethylene with color-coded bite block. Individually packaged, 48 per case. Latex Free....
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile and individually bagged....
Medicine Products: